News|Articles|February 29, 2024

Recap: Eating Disorders 2024

Here’s a look back at selections from our February content series on eating disorders.

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

ByLeah Kuntz

August 24th 2026

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

ByGerald A. Maguire, MD,Heidi Anne Duerr, MPH,Shahriar SheikhBahaei, PhD,Yoshikazu Kikuchi, MD, PhD,Lisa LaSalle PhD, CCC-SLP,Thomas J. Valente, MD,Anelise Junqueira Bohne, PhD, SLP,Tiago Proença dos Santos, MD,Gonçalo Leal, SLP,Devin Binder, MD, PhD,Gustavo Alva, MD, DFAPA,Greg Mattingly, MD

August 10th 2026

Unified Treatment Model Shows Long-Term Symptom Gains in BIPOC Patients With Eating Disorders

ByLeah Kuntz

July 31st 2026

The Weight of Performance: Athletic Identity and Eating Disorders in Male Athletes

ByMalea Jackson,Mena Mirhom, MD, FAPA

July 30th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Recap: Eating Disorders 2024

Related Content

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

Unified Treatment Model Shows Long-Term Symptom Gains in BIPOC Patients With Eating Disorders

The Weight of Performance: Athletic Identity and Eating Disorders in Male Athletes

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder